Genomic testing in pediatric epilepsy

Research output: Contribution to journalReview article

Abstract

Genomic testing has become routine in the diagnosis and management of pediatric patients with epilepsy. In a single test, hundreds to thousands of genes are examined for DNA changes that may not only explain the etiology of the patient’s condition but may also inform management and seizure control. Clinical genomic testing has been in clinical practice for less than a decade, and because of this short period of time, the appropriate clinical use and interpretation of genomic testing is still evolving. Compared to the previous era of single-gene testing in epilepsy, which yielded a diagnosis in <5% of cases, many clinical genomic studies of epilepsy have demonstrated a clinically significant diagnosis in 30% or more of patients tested. This review will examine key studies of the past decade and indicate the clinical scenarios in which genomic testing should be considered standard of care.

Original languageEnglish (US)
JournalCold Spring Harbor Molecular Case Studies
Volume5
Issue number4
DOIs
StatePublished - Jan 1 2019

Fingerprint

Pediatrics
Epilepsy
Testing
Standard of Care
Genes
Seizures
DNA

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Genetics
  • Genetics(clinical)

Cite this

Genomic testing in pediatric epilepsy. / Thodeson, Drew Michael; Park, Jason Y.

In: Cold Spring Harbor Molecular Case Studies, Vol. 5, No. 4, 01.01.2019.

Research output: Contribution to journalReview article

@article{c53be70c871a45198307c07d5799b995,
title = "Genomic testing in pediatric epilepsy",
abstract = "Genomic testing has become routine in the diagnosis and management of pediatric patients with epilepsy. In a single test, hundreds to thousands of genes are examined for DNA changes that may not only explain the etiology of the patient’s condition but may also inform management and seizure control. Clinical genomic testing has been in clinical practice for less than a decade, and because of this short period of time, the appropriate clinical use and interpretation of genomic testing is still evolving. Compared to the previous era of single-gene testing in epilepsy, which yielded a diagnosis in <5{\%} of cases, many clinical genomic studies of epilepsy have demonstrated a clinically significant diagnosis in 30{\%} or more of patients tested. This review will examine key studies of the past decade and indicate the clinical scenarios in which genomic testing should be considered standard of care.",
author = "Thodeson, {Drew Michael} and Park, {Jason Y}",
year = "2019",
month = "1",
day = "1",
doi = "10.1101/mcs.a004135",
language = "English (US)",
volume = "5",
journal = "Cold Spring Harbor molecular case studies",
issn = "2373-2873",
publisher = "Cold Spring Harbor Laboratory Press",
number = "4",

}

TY - JOUR

T1 - Genomic testing in pediatric epilepsy

AU - Thodeson, Drew Michael

AU - Park, Jason Y

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Genomic testing has become routine in the diagnosis and management of pediatric patients with epilepsy. In a single test, hundreds to thousands of genes are examined for DNA changes that may not only explain the etiology of the patient’s condition but may also inform management and seizure control. Clinical genomic testing has been in clinical practice for less than a decade, and because of this short period of time, the appropriate clinical use and interpretation of genomic testing is still evolving. Compared to the previous era of single-gene testing in epilepsy, which yielded a diagnosis in <5% of cases, many clinical genomic studies of epilepsy have demonstrated a clinically significant diagnosis in 30% or more of patients tested. This review will examine key studies of the past decade and indicate the clinical scenarios in which genomic testing should be considered standard of care.

AB - Genomic testing has become routine in the diagnosis and management of pediatric patients with epilepsy. In a single test, hundreds to thousands of genes are examined for DNA changes that may not only explain the etiology of the patient’s condition but may also inform management and seizure control. Clinical genomic testing has been in clinical practice for less than a decade, and because of this short period of time, the appropriate clinical use and interpretation of genomic testing is still evolving. Compared to the previous era of single-gene testing in epilepsy, which yielded a diagnosis in <5% of cases, many clinical genomic studies of epilepsy have demonstrated a clinically significant diagnosis in 30% or more of patients tested. This review will examine key studies of the past decade and indicate the clinical scenarios in which genomic testing should be considered standard of care.

UR - http://www.scopus.com/inward/record.url?scp=85070774739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070774739&partnerID=8YFLogxK

U2 - 10.1101/mcs.a004135

DO - 10.1101/mcs.a004135

M3 - Review article

VL - 5

JO - Cold Spring Harbor molecular case studies

JF - Cold Spring Harbor molecular case studies

SN - 2373-2873

IS - 4

ER -